Two Sigma Securities’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Two Sigma Securities’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,032	Closed	-$10.6K	–	3551
2023 Q1	$10.6K	Buy	+11,032	New	+$12.5K	﹤0.01%	2446
2022 Q1	–	Sell	-17,786	Closed	-$65K	–	2655
2021 Q4	$65K	Buy	+17,786	New	+$74.7K	﹤0.01%	1238

Other funds holding CYAD

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Two Sigma Securities's CYAD Position: Q2 2023 in Review

Two Sigma Securities sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q2 2023, closing a stake of 11,032 shares — an estimated $10.6K sold.

Two Sigma Securities first reported a position in CYAD in Q4 2021 and held it in 2 quarters. The position peaked at $65K in Q4 2021. 2 funds tracked by Wall St. Rank hold CYAD as of Q2 2023.

Two Sigma Securities reported no remaining Celyad Oncology SA American Depositary Shares position as of Q2 2023 after selling out during the quarter.
Two Sigma Securities sold 11,032 Celyad Oncology SA American Depositary Shares shares in Q2 2023, an estimated $10.6K.
Two Sigma Securities first reported a position in Celyad Oncology SA American Depositary Shares in Q4 2021 and held it in 2 quarters.
Two Sigma Securities's Celyad Oncology SA American Depositary Shares position peaked at $65K in Q4 2021.
2 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q2 2023.

Based on Two Sigma Securities's 13F filing for Q2 2023, filed 14 Aug 2023.